E N D
1. Funding for Haemophilia Care in Europe: A Taste of Things to Come? Adam Hutchings
GMAS LLP
WFH 24 September 2009
3. Haemophilia care has not been a primary target for cost savings Funding has often been provided direct to HTC’s from central government/sick funds
No Health Technology Assessment of haemophilia treatment approaches to date
Most new products launched in the last 10 years, all are available for use in nearly every market.
(Anecdotally) most patients who need it are receiving orthopaedic surgery – including patients with FVIII inhibitors
7. Economics of haemophilia are not unambiguous
8. Perception of unmet need in haemophilia is diminishing? Multiple effective treatments available
Product safety has progressed dramatically
Life expectancy is rising
Patient quality of life is close to population norms
Patients are starting to develop conditions of elderly (e.g osteoporosis)
Knowledge of disease history is lower in younger payers
9. Health Technology Assessment
10. Capped haemophilia budgets
11. National factor tenders
13. Establish relationships with policy makers and payers
Educate them about haemophilia
Early warning about impending action
Allows opportunity to sculpt the nature/scope of any review
Proactively develop local guidelines
German example: annual haemophilia roundtable with G-BA, patient representatives, physicians and industry
14. Data is key to defending treatment levels:
Clinical
Economic
Quality of life
‘Experiential’
These can be collected through
Patient records
Registries
Clinical trials
Patient surveys
Patients need to understand that the quality of their future care is dependent upon their participation in data collection programs